에 대한 최신 뉴스 Vivos Therapeutics (NASDAQ:VVOS) 주식

Vivos Therapeutics

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Equities

News

Markets

NVDA

SOFI

TMUS

TSLA

VVOS

수요일 주식 시장은 연방준비제도(연준)의 0.5% 금리 인하 발표로 인해 하락세로 돌아섰다. 이는 2020년 3월 이후 처음으로 미 중앙은행의 매우 기대받던 금리 인하 사이클의 시작을 알리는 것이다.

수요일 주목받은 주식 5종목: 엔비디아, T-모바일, 비보스 테라퓨틱스, 소파이 및 테슬라

Vivos Therapeutics Inc

WHLRD

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

WHLRP

WHLRL

WHLR

Millions of Americans face tougher times managing their bills as inflation bites. According to the U.S. Census Bureau, about 40% of consumers say it&#8217;s getting &#8220;somewhat&#8221; to &#8220;very difficult&#8221; to cover their monthly expenses.&nbsp;
This struggle is set to deepen with the return of student loan payments, which paused for years during the pandemic. Add to that the cost of summer child care and vacations and it's no wonder many are feeling the heat. But there's one payment you can't afford to put on the back burner: your student loans.
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/red-ventures"> The percentage may shock you</a>.</li>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
</ul>
Financial expert <a href="https://www.benzinga.com/personal-finance/24/08/40304035/suze-orman-says-ignoring-this-will-ruin-your-investment-future-heres-what-you-must-do-now-to-sec">Suze Orman</a>, host of the popular &#8220;Women &amp; Money&#8221; podcast, warns that skipping student loan payments is not an option. "It should be a priority," she said.
Pushing student loans aside with everything else on your plate might be tempting, but ignoring them could land you in hot water. The restart of these payments in fall 2023 has forced many people to figure out how to squeeze them back into already-tight budgets. However, Orman stresses that this is one bill you can't sweep under the rug.
Trending: Founder of Personal Capital and ex-CEO of PayPal<a href="https://www.benzinga.com/money/evergreen-money"> re-engineers traditional banking with this new high-yield account — start saving better today.</a>
Orman offers practical advice for those overwhelmed: &#8220;Make a plan or a budget that works so you can pay [your student loans] each month.&#8221; Her suggestion? Start by trimming the fat from your spending.&nbsp;
&#8220;Give up eating out or other unnecessary expenses so you can start making your payments,&#8221; she advises. Cutting back on indulgences can free up the cash needed to keep up with loan payments and it's a simple step toward regaining control over your finances.
Trending: Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Investing in its booming real estate market has never been more accessible.</a>
The silver lining is that the <a href="https://www.benzinga.com/personal-finance/24/09/40879305/the-22-6-trillion-crisis-neither-harris-nor-trump-mentioned-but-its-the-top-concern-for-millions">Biden </a>administration has rolled out a new income-driven repayment (IDR) plan called the Saving on a Valuable Education (SAVE) Plan. This plan could offer significant relief to borrowers, especially those on the lower end of the income scale.
According to the Department of Education, single borrowers earning $32,800 or less and families of four earning $67,500 or less won't need to make any payments at all. Even those earning more will see some savings – at least $1,000 annually compared to older IDR plans.
See Also: <a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv">IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</a>
"With the new guidelines, many people's payments will be cut in half," Orman explained. This makes it much more manageable to stay on top of those monthly payments, reducing the risk of falling behind. For borrowers feeling stretched thin, this adjustment might just be their lifeline.
There's no sugarcoating it – budgeting for loan payments can feel like a juggling act. But as Orman points out, it's a necessity. &#8220;People need to remember not to put off paying your student loans. It's not going away; it should be the first monthly bill you pay. You can't bankrupt your student loan.&#8221;
Read Next:
<ul>
<li>Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Personal Finance

Suze Orman Says Missing This One Crucial Monthly Payment Could Cost You Big – Here's The First Bill You Should Never Ignore

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Portland Gen Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) with a Hold rating and announces Price Target of $48.

Price Target

Initiation

Analyst Ratings

Jefferies Initiates Coverage On Portland Gen Electric with Hold Rating, Announces Price Target of $48

Jefferies analyst Paul Zimbardo initiates coverage on Dominion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>) with a Hold rating and announces Price Target of $58.

Jefferies Initiates Coverage On Dominion Energy with Hold Rating, Announces Price Target of $58

Jefferies analyst Julien Dumoulin-Smith initiates coverage on American Electric Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) with a Hold rating and announces Price Target of $107.

Jefferies Initiates Coverage On American Electric Power with Hold Rating, Announces Price Target of $107

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>) with a Hold rating and announces Price Target of $94.

Jefferies Initiates Coverage On Southern with Hold Rating, Announces Price Target of $94

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Idacorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDA#NYSE">IDA</a>) with a Hold rating and announces Price Target of $110.

Jefferies Initiates Coverage On Idacorp with Hold Rating, Announces Price Target of $110

Jefferies analyst Julien Dumoulin-Smith initiates coverage on WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) with a Hold rating and announces Price Target of $102.

Jefferies Initiates Coverage On WEC Energy Group with Hold Rating, Announces Price Target of $102

The head-to-head matchup between former President Donald Trump and Vice President Kamala Harris could come down to how several swing states fall in the<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election.</a>
A new poll shows which candidate is making up ground in the key seven states.
What Happened: Harris has been trending up <a href="https://www.benzinga.com/general/politics/24/09/40910999/trump-in-trouble-vice-president-harris-has-record-6-point-lead-in-2024-election-poll-after-debat">in 2024 election polls</a> of nationally registered voters, posting her largest lead in the weekly Morning Consult poll this week in the head-to-head matchup.
A new poll of <a href="https://www.benzinga.com/topic/swing-states">swing state</a> voters, which covers seven key battleground states, could show a different picture.
Here are the results from the September Emerson College swing state <a href="https://emersoncollegepolling.com/september-2024-swing-state-polls-trump-and-harris-locked-in-tight-presidential-race/">polls </a>with the results from August in parentheses:
<ul>
<li>Arizona: Trump 49% (50%), Harris 48% (47%)</li>
<li>Georgia: Trump 50% (48%), Harris 47% (49%)</li>
<li>Michigan: Harris 49% (50%), Trump 47% (47%)</li>
<li>Nevada: Trump 48% (48%), Harris 48% (49%)</li>
<li>North Carolina: Harris 49% (48%), Trump 48% (49%)</li>
<li>Pennsylvania: Trump 48% (48%), Harris 47% (48%)</li>
<li>Wisconsin: Trump 49% (49%), Harris 48% (48%)</li>
</ul>
The results show that Trump leads Harris in four of the seven states and is tied with the vice president in one state. Harris leads Trump in two states. Each candidate led three states in the August poll.
Trump gained support in one state and lost support in two states, with four states remaining the same from August. Harris gained support in two states and lost support in four states.
"There has been marginal movement in the presidential election since the late August Emerson swing state polls before the presidential debate," Emerson College Polling executive director Spencer Kimball said. 
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: The seven swing states in question together represent 93 electoral votes in the 2024 election. Six of the seven states above were won by Biden in the 2020 election with Trump winning North Carolina. Several of the states were flipped from Trump's win in the 2016 election.
A Marist poll recently found how swing state voters in Michigan, Pennsylvania and Wisconsin would vote in the 2024 election if it were held today. The race for Pennsylvania and Wisconsin was close with Trump and Harris tied in Pennsylvania and Harris leading by one point in Wisconsin.
In the state of Michigan, Harris had a five-point lead over Trump.
The three states together represent 44 electoral votes and could prove important in the 2024 election. Trump was the first Republican presidential candidate to sweep the three states since Ronald Reagan in 1984, <a href="https://nypost.com/2024/09/19/us-news/trump-harris-neck-and-neck-among-likely-voters-in-pennsylvania-and-wisconsin-veep-up-5-in-michigan-polls/">according </a>to the New York Post. Biden won all three of the states in the 2020 election.
All seven swing states see voters pick the economy as the top issue ahead of the election. Immigration, threats to democracy and housing affordability are also top voter issues in swing states.
With less than two months until the 2024 election, the race between Harris and Trump remains close and swing states continue to be one of the most monitored polling items given their importance.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent091924">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Shutterstock

Politics

Harris In Trouble? New Swing State Poll Shows Trump Gains Ground In Key Battleground Areas For 2024 Election

Jefferies analyst Paul Zimbardo initiates coverage on Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Hold rating and announces Price Target of $70.

Jefferies Initiates Coverage On Xcel Energy with Hold Rating, Announces Price Target of $70

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Alliant Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>) with a Hold rating and announces Price Target of $67.

Jefferies Initiates Coverage On Alliant Energy with Hold Rating, Announces Price Target of $67

Jefferies analyst Julien Dumoulin-Smith initiates coverage on OGE Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGE#NYSE">OGE</a>) with a Buy rating and announces Price Target of $46.

Jefferies Initiates Coverage On OGE Energy with Buy Rating, Announces Price Target of $46

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) with a Buy rating and announces Price Target of $97.

Jefferies Initiates Coverage On Ameren with Buy Rating, Announces Price Target of $97

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Evergy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVRG#NASDAQ">EVRG</a>) with a Buy rating and announces Price Target of $70.

EVRG

Jefferies Initiates Coverage On Evergy with Buy Rating, Announces Price Target of $70

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) with a Buy rating and announces Price Target of $104.

Jefferies Initiates Coverage On Pinnacle West Capital with Buy Rating, Announces Price Target of $104

Jefferies analyst Julien Dumoulin-Smith initiates coverage on Exelon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>) with a Buy rating and announces Price Target of $46.

Jefferies Initiates Coverage On Exelon with Buy Rating, Announces Price Target of $46

Jefferies analyst Paul Zimbardo initiates coverage on PPL (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>) with a Buy rating and announces Price Target of $38.

Jefferies Initiates Coverage On PPL with Buy Rating, Announces Price Target of $38

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings this morning!



Stocks continue to be volatile with the latest meme rally and earnings are also affecting many shares today.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) stock is rocketing more than 113% in what <a href="https://investorplace.com/2024/05/is-a-giant-short-squeeze-brewing-in-faraday-future-ffie-stock/">could be a short squeeze</a>.</li>



<li>Sintx Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sint-stock-quote/">SINT</a>) shares are soaring over 108% alongside heavy pre-market trading.</li>



<li>Greenwave Technology Solutions (NASDAQ:<a href="https://investorplace.com/stock-quotes/gwav-stock-quote/">GWAV</a>) stock is surging more than 52% with strong early morning trading.</li>



<li>Dolphin Entertainment (NASDAQ:<a href="https://investorplace.com/stock-quotes/dlpn-stock-quote/">DLPN</a>) shares are gaining over 28% with the release of its <a href="https://www.nasdaq.com/press-release/dolphin-entertainment-q1-2024-revenue-increases-54-year-over-year-to-a-record-%2415.2">Q1 2024 earnings report</a>.</li>



<li>Arcutis Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/arqt-stock-quote/">ARQT</a>) stock is rising more than 21% after <a href="https://www.msn.com/en-us/money/savingandinvesting/arqt-stock-earnings-arcutis-biotherapeutics-beats-eps-beats-revenue-for-q1-2024/ar-BB1moR0x">beating Q1 estimates</a>.</li>



<li>Dynatronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/">DYNT</a>) shares are climbing 20% despite a lack of news this morning.</li>



<li>Pineapple Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/pegy-stock-quote/">PEGY</a>) stock is increasing over 19% with heavy trading this morning.</li>



<li>Crown ElectroKinetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/crkn-stock-quote/">CRKN</a>) shares are jumping more than 18% today.</li>



<li>Bitfarms (NASDAQ:<a href="https://investorplace.com/stock-quotes/bitf-stock-quote/">BITF</a>) stock is heading over 18% higher after <a href="https://seekingalpha.com/news/4105038-bitfarms-boots-ceo-effective-immediately-reschedules-earnings">firing its CEO</a>.</li>



<li>Selina Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/slna-stock-quote/">SLNA</a>) shares are up close to 17% with strong trading on Wednesday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Virpax Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrpx-stock-quote/">VRPX</a>) stock is plummeting more than 40% as <a href="https://www.nasdaq.com/press-release/virpax-pharmaceuticals-reports-2024-first-quarter-results-and-recent-developments">earnings continue to weigh on the shares</a>.</li>



<li>Castellum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/">CTM</a>) shares are crashing over 38% alongside its <a href="https://www.nasdaq.com/press-release/castellum-inc.-announces-first-quarter-financial-results-2024-05-15">Q1 earnings report</a>.</li>



<li>Bolt Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bolt-stock-quote/">BOLT</a>) stock is diving more than 30% after <a href="https://www.nasdaq.com/press-release/bolt-biotherapeutics-reports-first-quarter-2024-results-announces-strategic-pipeline">releasing its Q1 results</a>.</li>



<li>Intrusion (NASDAQ:<a href="https://investorplace.com/stock-quotes/intz-stock-quote/">INTZ</a>) shares are tumbling over 29% with the release of its <a href="https://www.nasdaq.com/press-release/intrusion-inc.-reports-first-quarter-2024-results-2024-05-14">Q1 2024 earnings report</a>.</li>



<li>DLocal (NASDAQ:<a href="https://investorplace.com/stock-quotes/dlo-stock-quote/">DLO</a>) stock is taking a more than 27% beating after <a href="https://finance.yahoo.com/news/dlocal-dlo-lags-q1-earnings-221504662.html">missing Q1 estimates</a>.</li>



<li>Cheetah Net Supply Chain (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctnt-stock-quote/">CTNT</a>) shares are sliding 25% following a <a href="https://investorplace.com/2024/05/why-is-cheetah-net-ctnt-stock-up-200-today/">massive rally yesterday</a>.</li>



<li>VirTra (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtsi-stock-quote/">VTSI</a>) stock is falling over 23% with its <a href="https://www.nasdaq.com/press-release/virtra-reports-first-quarter-2024-financial-results-2024-05-14">latest earnings report</a>.</li>



<li>Aethlon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/aemd-stock-quote/">AEMD</a>) shares are decreasing more than 22% this morning.</li>



<li>Pixelworks (NASDAQ:<a href="https://investorplace.com/stock-quotes/pxlw-stock-quote/">PXLW</a>) stock is dropping over 20% <a href="https://www.msn.com/en-us/money/markets/pxlw-stock-earnings-pixelworks-meets-eps-beats-revenue-for-q1-2024/ar-BB1moUXx?ocid=finance-verthp-feeds">on lackluster earnings</a>.</li>



<li>Vivos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvos-stock-quote/">VVOS</a>) shares close out our pre-market stock movers down more than 20% <a href="https://www.proactiveinvestors.com/companies/news/1047558/vivos-therapeutics-reports-first-quarter-cost-savings-eyes-revenue-generating-initiative-1047558.html">with its Q1 earnings</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-may-15th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Vivos Therapeutics GAAP EPS of -$1.63, revenue of $3.4M

Vivos Therapeutics, Inc. (VVOS) Q1 2024 Earnings Call Transcript

Vivos gains as pilot program validates new market model

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Vivos Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvos-stock-quote/">VVOS</a>) just reported results for the second quarter of 2024.<ul><li>Vivos Therapeutics reported earnings per share of -60 cents. This was above the analyst estimate for EPS of -$1.05.</li><li>The company reported revenue of $4.05 million.</li><li>This was 12.61% better than the analyst estimate for revenue of $3.60 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vvos-stock-earnings-vivos-therapeutics-for-q2-of-2024/">VVOS Stock Earnings: Vivos Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VVOS Stock Earnings: Vivos Therapeutics Beats EPS, Beats Revenue for Q2 2024

Vivos Therapeutics GAAP EPS of -$0.60, revenue of $4.1M

Vivos Therapeutics, Inc. (VVOS) Q2 2024 Earnings Call Transcript

The latest announcement is out from Vivos Therapeutics ( ($VVOS) ). Vivos Therapeutics, Inc. is set to incentivize its workforce and align their in...

Vivos Therapeutics Enhances Incentives and Executive Pay Structure

Vivos surges on FDA nod for pediatric sleep apnea device

Vivos Therapeutics announces $4.3M registered direct offering of common stock

AEMD

ARQT

BITF

BOLT

CRKN

CTNT

DLPN

DYNT

FFIE

GWAV

INTZ

PEGY

PXLW

SINT

SLNA

VRPX

VTSI

Press Releases

Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Earnings

Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update

Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote "FOR" Re-Election of Its Highly Qualified Directors

Financing

Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance

Penny Stocks

Health Care

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

General

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

FDA Approval Sends Shares of this Healthcare Company Higher

Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CWCO

SKYX

American Shared Hospital Services Common Stock

American Shared Hospital

ATI Physical Therapy, Inc. Class A Common Stock

ATI Physical Therapy

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

CareMax

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Kindly MD

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

Nutex Health

Novo Integrated Sciences, Inc. - Common Stock

Novo Integrated Sciences

Ontrak

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Psychemedics

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

SHL Telemedicine

Syra Health

Ascendiant Capital

수요일 주식 시장은 연방준비제도(연준)의 <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">0.5% 금리 인하 발표</a>로 인해 하락세로 돌아섰다. 이는 2020년 3월 이후 처음으로 미 중앙은행의 매우 기대받던 금리 인하 사이클의 시작을 알리는 것이다.
다우존스 산업평균지수는 0.25% 하락한 41,503.10으로 마감했으며, S&amp;P 500은 0.3% 하락한 5,618.26으로 거래를 마쳤다. 나스닥도 0.3% 하락하여 17,573.30으로 마감했다.
수요일 하루 동안 소매 투자자들과 트레이더들의 주목을 받은 주요 주식들은 다음과 같다:
엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
엔비디아의 주식은 $113.37로 1.92% 하락 마감했다. 거래 중 최고가는 $117.7, 최저가는 $113.22였다. 해당 주식의 52주 최고가는 $140.76, 최저가는 $39.23다. 이 거대 기술 기업은 소프트웨어와 클라우드 컴퓨팅 서비스를 강화하기 위해 옥토AI(OctoAI) 스타트업을 1억 6,500만 달러에 <a href="https://www.benzinga.com/m-a/24/09/40926078/nvidia-considers-165m-octoai-acquisition-aims-to-strengthen-ai-and-cloud-dominance">인수</a>하는 것을 고려하고 있다.
T-모바일 US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)
T-모바일의 주식은 $196.68으로 2.97% 하락 마감했다. 거래 중 최고가는 $206.1, 최저가는 $195.47였다. 해당 주식의 52주 최고가는 $206.31, 최저가는 $135.82이다. 이 회사는 엔비디아, 에릭슨(Ericsson) 그리고 노키아(Nokia)와의 <a href="https://www.benzinga.com/markets/equities/24/09/40925493/t-mobile-partners-with-nvidia-ericsson-and-nokia-to-pioneer-ai-driven-mobile-networks">파트너십</a>을 발표하여 AI 기반 모바일 네트워크를 선도하고, 오픈AI와의 협약을 통해 고객 경험을 혁신하였다.
비보스 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>)
비보스 테라퓨틱스의 주식은 $4.13으로 47.50% 급등하여 마감했다. 거래 중 최고가는 $5.95, 최저가는 $3.02였다. 해당 주식의 52주 최고가는 $48.79, 최저가는 $1.91이다. 미국 식품의약국(FDA)은 <a href="https://www.benzinga.com/news/24/09/40920621/vivos-therapeutics-says-it-is-poised-to-disrupt-pediatric-sleep-apnea-market-secures-fda-approval-fo">소아 수면 무호흡증 시장을 혁신할</a> 기회를 제공하는 이 회사의 주력 구강 의료 기기에 510(k) 허가를 승인했다.
소파이 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)
소파이의 주식은 $8.11로 0.12% 하락 마감했다. 거래 중 최고가는 $8.53, 최저가는 $8.04였다. 해당 주식의 52주 최고가는 $10.49, 최저가는 $6.01이다. 투자자들이 연준의 <a href="https://www.benzinga.com/fintech/24/09/40928342/what-happened-with-sofi-stock-today">금리 인하를 예상</a>함에 따라 주식이 활발히 거래되었다.
테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주식은 $227.87로 0.48% 상승 마감했다. 거래 중 최고가는 $234.57, 최저가는 $226.55였다. 해당 주식의 52주 최고가는 $273.93, 최저가는 $138.8이다. 주식이 상승한 것은 연준의 <a href="https://www.benzinga.com/news/24/09/40927218/tesla-shares-surge-amid-fed-rate-cut-and-cybertruck-developments">금리 인하 결정</a>에 대한 시장의 전반적인 반응 때문일 가능성이 높다.
Photo by Phongphan on Shutterstock
벤징가는 <a href="Premarket Movers &amp; News">상위 프리마켓 동향 및 뉴스</a>로 하루 거래를 준비하세요.
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 생성되고 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Vivos Therapeutics

뉴스

에 대한 최신 뉴스 Vivos Therapeutics (NASDAQ:VVOS) 주식

목요일, 9월 19, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌